Drug intelligence / Profile preview

exendin-3

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

Exendin-3 is a 39-amino acid peptide naturally occurring in the venom of the Gila monster (*Heloderma horridum*). It belongs to the glucagon superfamily and serves as a potent agonist of the glucagon-like peptide 1 receptor (GLP-1R). Structurally, it is closely related to exendin-4 (exenatide), differing by only two amino acids at the N-terminus. While primarily used as a research tool to study GLP-1R signaling and pancreatic acinar function, exendin-3 has been investigated as a radiolabeled imaging agent (e.g., 68Ga-labeled exendin-3) for the localization of insulinomas using positron emission tomography (PET). At high concentrations, it also exhibits cross-reactivity with vasoactive intestinal peptide (VIP) receptors. It is not currently marketed as a commercial therapeutic pharmaceutical.

Other names
exendin 3exendin3exendin-3
02

Targets

GLP1R (GLP-1R)VPAC (VIP receptor family)

Beyond the preview

Go deeper on exendin-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on exendin-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call